Copeptin and risk stratification in patients with acute dyspnea

Critical Care

Volumn 14, Issue 6, 2010, Pages

  Potocki, Mihael ^a   Breidthardt, Tobias ^a   Mueller, Alexandra ^a   Reichlin, Tobias ^a   Socrates, Thenral ^a   Arenja, Nisha ^a   Reiter, Miriam ^a   Morgenthaler, Nils G ^b   Bergmann, Andreas ^b   Noveanu, Markus ^a   Buser, Peter T ^a   Mueller, Christian ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b BRAHMS AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; COPEPTIN; UNCLASSIFIED DRUG; VASOPRESSIN DERIVATIVE; BIOLOGICAL MARKER; COPEPTINS; GLYCOPEPTIDE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC TEST ACCURACY STUDY; DYSPNEA; FEMALE; HEART FAILURE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; STRATIFIED SAMPLE; SURVIVOR; ACUTE DISEASE; BLOOD; COMPARATIVE STUDY; FOLLOW UP; MIDDLE AGED; PROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL RATE;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COHORT STUDIES; DYSPNEA; FEMALE; FOLLOW-UP STUDIES; GLYCOPEPTIDES; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE;

EID: 78549290339     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9336     Document Type: Article

References (37)

1. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002, 347:161-167. 10.1056/NEJMoa020233, 12124404.
2. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P, Pfisterer M, Perruchoud AP. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004, 350:647-654. 10.1056/NEJMoa031681, 14960741.
3. Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society. Am J Respir Crit Care Med 1999, 159:321-340.
4. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336:243-250. 10.1056/NEJM199701233360402, 8995086.
5. Fonarow GC, Adams KF, Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005, 293:572-580. 10.1001/jama.293.5.572, 15687312.
6. Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, Buttimore RC, Lainchbury JG, Elliott JM, Ikram H, Crozier IG, Smyth DW. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998, 97:1921-1929.
7. Knudsen CW, Clopton P, Westheim A, Klemsdal TO, Wu AH, Duc P, McCord J, Nowak RM, Hollander JE, Storrow AB, Abraham WT, McCullough PA, Maisel AS, Omland T. Predictors of elevated B-type natriuretic peptide concentrations in dyspneic patients without heart failure: an analysis from the breathing not properly multinational study. Ann Emerg Med 2005, 45:573-580. 10.1016/j.annemergmed.2005.01.027, 15940086.
8. Ruggiano G, Camajori-Tedeschini R, Lombardi V, Pratesi M, Rosselli A. 287: Plasma BNP Levels in the Risk Stratification of Septic Patients at the Emergency Department. Annals of Emergency Medicine 2008, 51:557-558.
9. Christ M, Thuerlimann A, Laule K, Klima T, Hochholzer W, Perruchoud AP, Mueller C. Long-term prognostic value of B-type natriuretic peptide in cardiac and non-cardiac causes of acute dyspnoea. Eur J Clin Invest 2007, 37:834-841. 10.1111/j.1365-2362.2007.01871.x, 17931382.
10. Gegenhuber A, Mueller T, Dieplinger B, Poelz W, Pacher R, Haltmayer M. B-type natriuretic peptide and amino terminal proBNP predict one-year mortality in short of breath patients independently of the baseline diagnosis of acute destabilized heart failure. Clin Chim Acta 2006, 370:174-179. 10.1016/j.cca.2006.02.010, 16600203.
11. Itoi K, Jiang YQ, Iwasaki Y, Watson SJ. Regulatory mechanisms of corticotropin-releasing hormone and vasopressin gene expression in the hypothalamus. J Neuroendocrinol 2004, 16:348-355. 10.1111/j.0953-8194.2004.01172.x, 15089973.
12. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 2005, 46:1785-1791. 10.1016/j.jacc.2005.02.095, 16286160.
13. Jochberger S, Mayr VD, Luckner G, Wenzel V, Ulmer H, Schmid S, Knotzer H, Pajk W, Hasibeder W, Friesenecker B, Mayr AJ, Dunser MW. Serum vasopressin concentrations in critically ill patients. Crit Care Med 2006, 34:293-299. 10.1097/01.CCM.0000198528.56397.4F, 16424705.
14. Robertson GL, Mahr EA, Athar S, Sinha T. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest 1973, 52:2340-2352. 10.1172/JCI107423, 333039, 4727463.
15. Preibisz JJ, Sealey JE, Laragh JH, Cody RJ, Weksler BB. Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension 1983, 5:I129-138.
16. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006, 52:112-119. 10.1373/clinchem.2005.060038, 16269513.
17. Voors AA, von Haehling S, Anker SD, Hillege HL, Struck J, Hartmann O, Bergmann A, Squire I, van Veldhuisen DJ, Dickstein K. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J 2009, 30:1187-1194. 10.1093/eurheartj/ehp098, 19346228.
18. Masia M, Papassotiriou J, Morgenthaler NG, Hernandez I, Shum C, Gutierrez F. Midregional pro-A-type natriuretic peptide and carboxy-terminal provasopressin may predict prognosis in community-acquired pneumonia. Clin Chem 2007, 53:2193-2201. 10.1373/clinchem.2007.085688, 17951293.
19. Neuhold S, Huelsmann M, Strunk G, Stoiser B, Struck J, Morgenthaler NG, Bergmann A, Moertl D, Berger R, Pacher R. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol 2008, 52:266-272. 10.1016/j.jacc.2008.03.050, 18634981.
20. Stolz D, Christ-Crain M, Morgenthaler NG, Leuppi J, Miedinger D, Bingisser R, Muller C, Struck J, Muller B, Tamm M. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007, 131:1058-1067. 10.1378/chest.06-2336, 17426210.
21. Khan SQ, Dhillon OS, O'Brien RJ, Struck J, Quinn PA, Morgenthaler NG, Squire IB, Davies JE, Bergmann A, Ng LL. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 2007, 115:2103-2110. 10.1161/CIRCULATIONAHA.106.685503, 17420344.
22. Gegenhuber A, Struck J, Dieplinger B, Poelz W, Pacher R, Morgenthaler NG, Bergmann A, Haltmayer M, Mueller T. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 2007, 13:42-49. 10.1016/j.cardfail.2006.09.004, 17339002.
23. Dieplinger B, Gegenhuber A, Haltmayer M, Mueller T. Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath. Heart 2009, 95:1508-1513. 10.1136/hrt.2009.170696, 19525245.
24. Collinson PO, Barnes SC, Gaze DC, Galasko G, Lahiri A, Senior R. Analytical performance of the N terminal pro B type natriuretic peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers. Eur J Heart Fail 2004, 6:365-368. 10.1016/j.ejheart.2004.01.011, 14987590.
25. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Preliminary evaluation of the AxSYM B-type natriuretic peptide (BNP) assay and comparison with the ADVIA Centaur BNP assay. Clin Chem 2004, 50:1104-1106. 10.1373/clinchem.2004.031484, 15161739.
26. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983, 148:839-843.
27. Pencina MJ, D'Agostino RB, D'Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172. discussion 207-112, 10.1002/sim.2929, 17569110.
28. Katan M, Morgenthaler N, Widmer I, Puder JJ, Konig C, Muller B, Christ-Crain M. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett 2008, 29:341-346.
29. Seligman R, Papassotiriou J, Morgenthaler NG, Meisner M, Teixeira PJ. Copeptin, a novel prognostic biomarker in ventilator-associated pneumonia. Crit Care 2008, 12:R11. 10.1186/cc6780, 2374597, 18252006.
30. Oghlakian G, Klapholz M. Vasopressin and vasopressin receptor antagonists in heart failure. Cardiol Rev 2009, 17:10-15. 10.1097/CRD.0b013e318190e72c, 19092365.
31. Lee CR, Watkins ML, Patterson JH, Gattis W, O'Connor CM, Gheorghiade M, Adams KF. Vasopressin: a new target for the treatment of heart failure. Am Heart J 2003, 146:9-18. 10.1016/S0002-8703(02)94708-3, 12851603.
32. Westphal M, Sielenkamper AW, Van Aken H, Stubbe HD, Daudel F, Schepers R, Schulte S, Bone HG. Dopexamine reverses the vasopressin-associated impairment in tissue oxygen supply but decreases systemic blood pressure in ovine endotoxemia. Anesth Analg 2004, 99:878-885. table of contents, 10.1213/01.ANE.0000131970.54062.1C, 15333425.
33. Perez R, Espinoza M, Riquelme R, Parer JT, Llanos AJ. Arginine vasopressin mediates cardiovascular responses to hypoxemia in fetal sheep. Am J Physiol 1989, 256:R1011-1018.
34. Jin HK, Yang RH, Chen YF, Thornton RM, Jackson RM, Oparil S. Hemodynamic effects of arginine vasopressin in rats adapted to chronic hypoxia. J Appl Physiol 1989, 66:151-160.
35. Sharples PM, Seckl JR, Human D, Lightman SL, Dunger DB. Plasma and cerebrospinal fluid arginine vasopressin in patients with and without fever. Arch Dis Child 1992, 67:998-1002. 10.1136/adc.67.8.998, 1793597, 1520019.
36. Januzzi JL, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown DF, Foran-Melanson S, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005, 95:948-954. 10.1016/j.amjcard.2004.12.032, 15820160.
37. Pratt CM, Greenway PS, Schoenfeld MH, Hibben ML, Reiffel JA. Exploration of the precision of classifying sudden cardiac death. Implications for the interpretation of clinical trials. Circulation 1996, 93:519-524.